期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ()
Background: Cardiovascular (CVS) diseases are the leading cause of death worldwide and patients with rheumatic diseases have an increased CVS. CVS ris......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ()
Background: The aim of this study was to examine the impact of underweight, overweight and obesity on clinical outcomes and treatment responses to bio......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ()
The treatment of inflammatory arthritis has been revolutionised by the introduction of biologic treatments. Many biologic agents are currently license......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ()
Aims: Psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to underlying inflammation. Whether inflammatory burden and drugs u......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ()
Objective: Although a positive result of labial salivary gland biopsy (LSGB) is critical for the diagnosis of Sjogren's syndrome, rheumatologists pref......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ()
Introduction: To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthri......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ()
Aims: We aimed to evaluate the risk of valvular heart disease (VHD) among patients with ankylosing spondylitis (AS). Methods: This was a population-ba......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ()
Aims: To investigate the long-term survival of patients with primary Sjogren's syndrome (pSS) in China. Methods: Patients with pSS who fulfilled the 2......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ()
Objective: Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic inflammatory disorder and the underlying pathoge......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ()
Background: Overexpression of cyclin-dependent kinase 7 (CDK7) is a well-known pathogenic feature of various malignancies and a sign of a more dismal ......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ()
Objective: To evaluate the comparative efficacy and safety of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs (bDMA......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021; 13 ()
Background: Osteonecrosis of the femoral head (ONFH) remains a major cause of disability in patients with systemic lupus erythematosus (SLE) and serio......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2020; 12 ()
Objectives: This study aimed to investigate the efficacy and safety of tocilizumab (TCZ) in severe and refractory parenchymal neuro-Behcet's syndrome ......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2020; 12 ()
Background: The presence of > 3 corner inflammatory lesions has been proposed as the definition of a positive spinal magnetic resonance imaging (MR......
期刊： THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2020; 12 ()
Systemic sclerosis (SSc) is a life-threatening connective tissue disorder of unknown etiology characterized by widespread vascular injury and dysfunct......
